Bristol-Myers Squibb (NYSE:BMY) recently announced an update from the FDA on CAMZYOS®, focusing on simplified treatment ...

Cancer drugs' sexual toxicity warrants a "call to action" among oncologists to address the problem. ( Lancet Oncology) U.S.

Bristol-Myers Squibb (NYSE:BMY) recently announced an update from the FDA on CAMZYOS®, focusing on simplified treatment ...

There is currently no strong evidence that additional immune therapy benefits patients with renal cell carcinoma who were ...

During a live event, Martin Voss, MD, reviewed the trials of lenvatinib plus pembrolizumab, cabozantinib plus nivolumab, and ...

Four healthcare dividend stocks with significant upside potential and safe dividends look like outstanding investing ideas ...